About Lenz Therapeutics
Lenz Therapeutics is a private company based in Del Mar, California. It has reported $136,152,298 raised in four offerings on Form D since June 2016. Its chief executive is Evert Schimmelpennink.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Mar 6, 2023 | Mar 10, 2023 | $83,499,961fully sold | 27 | $3.0M | EquityRule 506(b) | Form D ↗ |
| Oct 30, 2020 | Nov 9, 2020amended Nov 22, 2022 | $49,002,348fully sold | 45 | $1.0M | Equity, Options, Securities on exerciseRule 506(b) | Form D/A ↗1 earlier filing |
| Aug 5, 2020 | Sep 14, 2020 | $250,000fully sold | 25 | $10,000 | Debt, OptionsRule 506(b) | Form D ↗ |
| Jun 3, 2016 | Jun 30, 2016 | $3,399,989of $3.4M target | 45 | $75,555 | EquityRule 506(b) | Form D ↗ |
| Total, four offerings | $136,152,298 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Lenz Therapeutics's Form D filed Mar 10, 2023.
ES
Evert Schimmelpennink
President & CEO, director
JM
James McCollum
Director
CO
Clare Ozawa
Director
ZS
Zach Scheiner
Director
SL
Stefan Larson
Director
FG
Frederic Guerard
Director
Also a president and chief executive officer, director at Qlaris Bio and a director at Spiral Therapeutics.
Earlier filings also listed Fred Guerard (director, last listed Nov 2022), Mark Lester (executive officer and director, last listed Sep 2020) and Gerald Horn (executive officer and director, last listed Sep 2020).